Can Molecular Imaging Provide Key Insights on Obesity Interventions?
New research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference suggests that neuroreceptor differences in reactions to visual food cues between obese people and normal-weight individuals may improve the understanding of underlying mechanisms that contribute to obesity.
Changes in how nicotinic acetylcholine receptors respond to visual food cues may have implications in the development of interventions to address obesity, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Utilizing the imaging agent 18F-flubatine with positron emission tomography/magnetic resonance imaging (PET/MRI), researchers reviewed data from 15 obese individuals and 16 people with normal weight. According to the study, all the study participants had imaging twice, once in a resting state and once while looking at photos of high-caloric food, on separate days.
While the researchers saw no difference between the groups in resting state imaging, the obese cohort had a higher total distribution of 18F-flubatine and a stronger connectivity with the salience network when viewing food cues, according to the researchers.
The researchers also noted a correlation between the nucleus accumbens and disinhibition measures in obese individuals. Alternately, the study authors found those with normal weight demonstrated a correlation between satiety measurement and total volume distribution in the hypothalamus.
The study authors said cholinergic changes they saw with nicotinic acetylcholine receptors in response to visual food cues may have a potential impact for obesity interventions.
“We anticipate that the results of our study will pave the way for novel drug treatments and behavioral interventions to effectively combat obesity worldwide,” noted Osama Sabri, M.D., Ph.D, a professor, director, and chairman of the Department of Nuclear Medicine at the University of Leipzig in Leipzig, Germany. “In addition, the imaging technology utilized in this study holds promise for identifying biomarkers that can aid in patient stratification and facilitate personalized medicine approaches in the near future.”
(Editor’s note: For related content, see “SPECT Scans Reveal Link Between Obesity, Brain Blood Flow and Alzheimer’s” and “New PET Perfusion Radiotracer May Improve Coronary Artery Disease Diagnosis.”)
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
